MADRID (Reuters) – Rovi laboratories said Wednesday
the European Commission approved its drug to treat ivabradina
chronic heart failure.
“Ivabradina treatment significantly reduces the
“
risk of death and hospitalization for failure
heart, prevents the progression of the disease and improving the
“
quality of life of patients with this disease”, indicated the
group said in a statement.
Heart failure means that the heart can no longer
pump enough blood oxygenated to the rest of the body.
Rovi pointed out that this disease affects only in Spain to 1.2
millions of people, and added that the compound already approved is
marketed in the country of Iberian for the treatment of angina
stable.
